Recovery Outlook from Meningioma

• How serious is a meningioma?

• What is the life expectancy of someone with a meningioma?

• What is the life expectancy for meningioma by grade?

• The importance of follow-up care and monitoring

• Eliminate uncertainties by seeking a second opinion 

Meningiomas are tumors that grow from the meninges (membranes surrounding the brain and spinal cord) and are typically benign (noncancerous). However, they can potentially cause serious neurological problems depending on their size and location. 

In the United States, meningiomas account for about 39% of all primary brain tumors. While most meningiomas are benign, they can grow and compress nearby structures, leading to serious neurological and life-threatening problems. Meningiomas can occur at any age, but they are most common in people over 65.

Meningioma prognosis can be difficult for patients and caregivers to understand. Meningiomas are graded on a scale from I to III, with World Health Organization (WHO) Grade I being the least aggressive (growing slowly) and WHO Grade III being the most aggressive (growing fast). To help you learn more about meningioma, its various kinds (grades), and the life expectancy for each grade, I have put together this detailed guide with frequently asked questions about meningioma prognoses.

Since meningiomas are benign tumors, they aren't typically life-threatening. Unlike cancerous tumors, they don't commonly spread to other parts of the brain and distant parts of the body. Instead, a meningioma grows slowly, which allows the brain to compensate to a certain degree. Significant symptoms aren’t usually present in the early stages, but this can change if the tumor continues to grow and achieves a certain size.

While most meningiomas are initially asymptomatic, symptoms caused by a meningioma may include:

• Headaches
• Vision problems, such as blurriness
• Language difficulty
• Memory loss
• Seizures
• Nausea and vomiting
• Drowsiness and confusion
• Change in behavior or personality
• Weakness or numbness in the arms or legs
• Hearing loss or ringing in the ears

The life expectancy of someone with a meningioma depends on the grade and type of the tumor. Age and health status are also major factors when determining life expectancy. Generally, patients with tumors of lower grades have better prognoses. In contrast, patients with tumors of higher grades have poorer prognoses.

Regardless of the tumor grade, outcomes are generally more favorable as compared to those of more aggressive tumors such as glioblastoma. Tumors located around the brainstem, spinal cord, or near critical blood vessels are more difficult to remove completely surgically and are therefore associated with lower survival rates. Treatment options, such as surgery, radiation therapy, and chemotherapy, can also affect life expectancy.

The 5-year survival rate for individuals with noncancerous meningioma (Grade I) is highly positive with 96% for ages 14 years or below, 97% for ages 15 to 39, and 87% for those 40 and above. A person's age at diagnosis and the tumor's grade and location may affect the overall prognosis. For malignant meningiomas (Grade III), the 5-year survival rate is over 67%, while the 10-year survival rate is about 61%. 

Benign or Grade I meningiomas are slow-growing and are not cancerous. That is, they do not spread to other brain or body parts. The cells in benign meningiomas look somewhat similar to normal cells and the tumors are usually encapsulated.

Benign meningiomas are often treated with surgery, with a low recurrence rate. Fortunately, the 5-year survival rate for patients with benign meningiomas is over 95%.

While the news of having a WHO Grade I meningioma may sound a bit relieving, understanding what each tumor grade means for your prognosis is important. As previously stated, the WHO uses a system to grade meningiomas from I to III, with WHO Grade III being the most serious. 

Meningioma grading is based on how the cells of the tumor look under a microscope. Tumors with a lower grade are slow-growing, less invasive, and are associated with a longer life expectancy. Tumors with a higher grade are more aggressive, faster-growing, and are associated with a shorter life expectancy.

This is the least invasive and slowest-growing type of meningioma. The cells in Grade I tumors look similar to normal cells, showing little to no abnormal growth. Over 95% of people with WHO Grade I meningiomas live five or more years after diagnosis. 

Due to their low-grade nature, non-symptomatic tumors are often monitored with magnetic resonance imaging (MRI) scans every 6 to 12 months rather than immediate treatment. Your neurosurgeon may recommend treatment if the tumor is growing or causing symptoms.

WHO Grade II meningioma accounts for 18% of meningioma cases. Unlike Grade I meningioma, there are increased cell and tissue abnormalities under biopsy examination. The cells in Grade II tumors look abnormal under a microscope, and the tumor is less likely to be encapsulated. These are the reasons why this tumor grade is also called an atypical meningioma. It grows faster than a Grade I tumor and is characterized by brain invasion. 

A Grade II meningioma has a higher recurrence rate than a Grade I meningioma. If a part of the tumor remains, recurrence or regrowth is more likely. Repeated surgical explorations can reduce quality of life. Thus, the goal of surgery is for complete (also known as gross) total resection during the first surgery. Nevertheless, the 5-year survival rate for patients with Grade II meningioma is good, about 97.5%, with a median survival time of 167 months. These patients typically undergo surgical removal and in some cases radiation therapy after surgery.

This is the most aggressive type of meningioma, with a 5-year survival rate of about 60%. WHO Grade III meningiomas are highly-invasive (malignant) and fast-growing tumors. The cells in Grade III tumors look highly abnormal under a microscope, with little to no resemblance to normal cells. 

These tumors are not encapsulated and can spread into nearby tissues. WHO Grade III meningiomas are more likely to recur after treatment and can be difficult to remove completely. Radiation therapy or chemotherapy may be recommended in addition to surgery.

Recovery from meningioma involves more than the initial treatment phase. It extends into a commitment to long-term wellness through regular follow-up care and monitoring.

After undergoing surgery, radiation therapy, or other forms of intervention, patients and their caregivers play a pivotal role in maintaining vigilance over their health to detect potential signs of recurrence and ensure the best possible outcome.

Regular follow-up appointments with healthcare professionals are integral components of post-meningioma recovery. These check-ups provide a platform for comprehensive assessments, enabling medical experts to monitor the patient's overall health, evaluate treatment efficacy, and detect any early signs of recurrence. 

The frequency of these appointments may vary based on individual circumstances and the specific treatment plan. However, it typically involves regular visits in the initial years following treatment, which is commonly structured as follows:

• Early Postoperative Period: In the initial weeks following surgery or treatment, patients might need to attend check-ups more frequently. These can be weekly or biweekly to ensure proper healing of the surgical site, manage any postoperative complications such as infection or swelling, and adjust medications as required.
• First Year After Treatment: After the first year, appointments are often scheduled every 6 to 12 months. During these visits, the patient undergoes neurological examinations and brain imaging studies, such as MRI or CT scans, to monitor for tumor recurrence or growth. Cognitive and psychological assessments may also be conducted to evaluate any changes in mental function or mood following the treatment.
• Second Year, Onward: If the patient is stable and shows no signs of tumor recurrence, the interval between visits may be extended. The monitoring during these visits includes neurological assessment and imaging, with additional attention to any long-term treatment effects and the patient's quality of life.
• Long-term Follow-up: Beyond the second year, patients might continue to have check-ups every 1-2 years. These visits, which often continue for many years, are essential to detecting late recurrences or new tumors at an early stage. Depending on the aggressiveness of the original tumor and the types of treatment received, some patients may need more frequent follow up visits throughout their lives.

Fear and confusion often accompany a meningioma diagnosis. In the face of such news, several uncertainties can make it tough to handle the diagnosis and new way of life, but knowledge can empower and guide you through the journey ahead. 

In this critical moment, seeking guidance from trusted neurosurgical experts is crucial. Get multiple perspectives to ensure an accurate assessment of your condition. Consult trusted experts like Dr. Aaron Cohen-Gadol for a second opinion. 

With a distinguished career marked by over 7,000 complex brain surgeries and more than 530 neurosurgical publications, Dr. Cohen offers his expertise and dedication to patient care as an indispensable resource in your brain tumor journey. 

Schedule a consultation and request a second opinion from Dr. Cohen today!

Meningioma prognosis largely depends on the grade of the tumor. Grading is based on how the cells look under a microscope. Low-grade meningiomas (WHO Grade I) have a very good prognosis, better than WHO Grade III (malignant) meningiomas. 

It’s not uncommon for there to be confusion surrounding the terminology of meningiomas. Tumor grading requires a specimen which is collected through a biopsy during the surgery for tumor removal. It is important to understand the principles of tumor grading as it fundamentally influences prognosis and long-term patient outcomes.

• American Association of Neurological Surgeons 
• National Cancer Institute 
• American Brain Tumor Society 
• National Brain Tumor Society